JP2016524463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524463A5 JP2016524463A5 JP2016509450A JP2016509450A JP2016524463A5 JP 2016524463 A5 JP2016524463 A5 JP 2016524463A5 JP 2016509450 A JP2016509450 A JP 2016509450A JP 2016509450 A JP2016509450 A JP 2016509450A JP 2016524463 A5 JP2016524463 A5 JP 2016524463A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding molecule
- specific antigen
- seq
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 146
- 102000036639 antigens Human genes 0.000 claims description 146
- 108091007433 antigens Proteins 0.000 claims description 146
- 230000027455 binding Effects 0.000 claims description 70
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 241000251729 Elasmobranchii Species 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 7
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361815043P | 2013-04-23 | 2013-04-23 | |
| US61/815,043 | 2013-04-23 | ||
| PCT/EP2014/058251 WO2014173959A2 (en) | 2013-04-23 | 2014-04-23 | Synthetic library of specific binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016524463A JP2016524463A (ja) | 2016-08-18 |
| JP2016524463A5 true JP2016524463A5 (cg-RX-API-DMAC7.html) | 2017-06-08 |
| JP6616284B2 JP6616284B2 (ja) | 2019-12-04 |
Family
ID=50543598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509450A Active JP6616284B2 (ja) | 2013-04-23 | 2014-04-23 | 特異的結合分子の人工ライブラリー |
| JP2016509455A Active JP6591964B2 (ja) | 2013-04-23 | 2014-04-23 | Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509455A Active JP6591964B2 (ja) | 2013-04-23 | 2014-04-23 | Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10472410B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3683312B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6616284B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160010466A (cg-RX-API-DMAC7.html) |
| CN (2) | CN105531370A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014257549B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112015026716A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2909921C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2989203T3 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2015146418A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014173975A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2847229B1 (en) | 2012-05-07 | 2022-09-07 | Elasmogen Limited | Single domain binding molecule |
| KR20160010466A (ko) | 2013-04-23 | 2016-01-27 | 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 | Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리 |
| US10479990B2 (en) | 2014-06-26 | 2019-11-19 | Ossianix, Inc. | Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds |
| AU2015342264B2 (en) * | 2014-11-03 | 2021-08-12 | Merck Patent Gmbh | Methods for generating bispecific shark variable antibody domains and use thereof |
| WO2016077840A2 (en) | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS |
| ITUB20151014A1 (it) * | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
| KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| CN107130300A (zh) * | 2016-10-08 | 2017-09-05 | 深圳劲宇生物科技有限公司 | 一种dna编码分子库的合成方法及dna模板 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN111479825A (zh) * | 2017-09-27 | 2020-07-31 | 艾莱斯摩根公司 | 特异性结合分子 |
| US11180544B2 (en) * | 2017-11-07 | 2021-11-23 | City University Of Hong Kong | Method of producing antibody fragment |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2020056327A1 (en) | 2018-09-14 | 2020-03-19 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| CN111197074B (zh) * | 2018-11-20 | 2023-08-15 | 深圳华大生命科学研究院 | 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用 |
| US20220130494A1 (en) * | 2019-02-11 | 2022-04-28 | Neal W. Woodbury | Systems, methods, and media for molecule design using machine learning mechanisms |
| GB201906997D0 (en) * | 2019-05-17 | 2019-07-03 | Elasmogen Ltd | Conjugates |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| EP4143582A4 (en) * | 2020-05-01 | 2024-09-25 | University of Pittsburgh - of the Commonwealth System of Higher Education | COMPOSITIONS AND METHODS FOR IDENTIFYING NANOBODIES AND NANOBODY AFFINITIES |
| CN112301431B (zh) * | 2020-08-12 | 2023-01-31 | 华东理工大学 | 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法 |
| GB202020152D0 (en) | 2020-12-18 | 2021-02-03 | Elasmogen Ltd | Fast-track humanisation of specific binding molecules |
| GB202020154D0 (en) * | 2020-12-18 | 2021-02-03 | Almac Discovery Ltd | ROR1-specific variant antigen binding molecules |
| WO2022212429A1 (en) * | 2021-03-31 | 2022-10-06 | Sachdev Sidhu | Anti-viral compositions for rift valley fever virus infections and methods of using same |
| EP4141028A1 (en) | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
| GB202407865D0 (en) | 2024-06-03 | 2024-07-17 | Elasmogen Ltd | Self immolative compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008419D0 (en) * | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| ES2337986T3 (es) | 2001-08-10 | 2010-05-03 | Aberdeen University | Dominios de union de antigenos de peces. |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CA2536238C (en) * | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| WO2005021719A2 (en) * | 2003-08-27 | 2005-03-10 | Proterec Ltd | Libraries of recombinant chimeric proteins |
| CA2567655C (en) * | 2004-06-02 | 2015-06-30 | Diatech Pty Ltd | Binding moieties based on shark ignar domains |
| BRPI0511782B8 (pt) * | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
| JPWO2006003999A1 (ja) * | 2004-07-05 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗ヒトｂ７ｒｐ−１抗体およびその抗体フラグメント |
| AU2006227377B2 (en) * | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
| EP2351842A1 (en) | 2005-03-25 | 2011-08-03 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| CA2854576A1 (en) * | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| JP2010502208A (ja) | 2006-09-08 | 2010-01-28 | アブリンクス エン．ヴェー． | 半減期の長い血清アルブミン結合タンパク質 |
| ATE536369T1 (de) | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
| WO2009026638A1 (en) | 2007-08-31 | 2009-03-05 | Melbourne Health | Marine-animal derived therapeutic and diagnostic agents for hepatitis b |
| US8524863B2 (en) * | 2008-10-06 | 2013-09-03 | Commonwealth Scientific And Industrial Research Organisation | Amyloid-beta peptide crystal structure |
| CA2738801A1 (en) * | 2008-10-07 | 2010-04-15 | Zap Holdings Limited | Synchronization of relational databases with olap cubes |
| WO2011056056A2 (es) | 2009-11-04 | 2011-05-12 | Laboratorios Silanes, S.A. De C.V. | Dominios vhnar anti -citocinas |
| EP2646461A2 (en) * | 2010-12-03 | 2013-10-09 | Cyclogenix Ltd | VARIANTS OF igNAR |
| EP2847229B1 (en) | 2012-05-07 | 2022-09-07 | Elasmogen Limited | Single domain binding molecule |
| CN103031304A (zh) * | 2012-12-27 | 2013-04-10 | 苏州大学 | 一种微小rna用于调控b7-h2基因表达 |
| KR20160010466A (ko) | 2013-04-23 | 2016-01-27 | 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 | Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리 |
-
2014
- 2014-04-23 KR KR1020157033307A patent/KR20160010466A/ko not_active Withdrawn
- 2014-04-23 EP EP19208141.2A patent/EP3683312B1/en active Active
- 2014-04-23 CN CN201480035842.9A patent/CN105531370A/zh active Pending
- 2014-04-23 RU RU2015146418A patent/RU2015146418A/ru not_active Application Discontinuation
- 2014-04-23 JP JP2016509450A patent/JP6616284B2/ja active Active
- 2014-04-23 CA CA2909921A patent/CA2909921C/en active Active
- 2014-04-23 KR KR1020157033430A patent/KR102320189B1/ko active Active
- 2014-04-23 WO PCT/EP2014/058276 patent/WO2014173975A1/en not_active Ceased
- 2014-04-23 RU RU2015146419A patent/RU2015146419A/ru not_active Application Discontinuation
- 2014-04-23 CN CN201480035865.XA patent/CN105492610B/zh active Active
- 2014-04-23 US US14/785,975 patent/US10472410B2/en active Active
- 2014-04-23 EP EP14720559.5A patent/EP2989204B1/en active Active
- 2014-04-23 DK DK14718999.7T patent/DK2989203T3/da active
- 2014-04-23 BR BR112015026716A patent/BR112015026716A2/pt not_active IP Right Cessation
- 2014-04-23 US US14/786,074 patent/US10202438B2/en active Active
- 2014-04-23 AU AU2014257549A patent/AU2014257549B2/en active Active
- 2014-04-23 AU AU2014257565A patent/AU2014257565A1/en not_active Abandoned
- 2014-04-23 EP EP14718999.7A patent/EP2989203B1/en active Active
- 2014-04-23 BR BR112015026729A patent/BR112015026729A2/pt not_active Application Discontinuation
- 2014-04-23 CA CA2909923A patent/CA2909923A1/en not_active Abandoned
- 2014-04-23 JP JP2016509455A patent/JP6591964B2/ja active Active
- 2014-04-23 WO PCT/EP2014/058251 patent/WO2014173959A2/en not_active Ceased
-
2019
- 2019-02-11 US US16/271,959 patent/US11459377B2/en active Active
- 2019-07-18 AU AU2019206064A patent/AU2019206064A1/en not_active Abandoned